- Home
- BCTX vs IRIX Comparison
BCTX vs IRIX Comparison
Compare BCTX & IRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- IRIX
- Stock Information
- Founded
- BCTX 2014
- IRIX 1989
- Country
- BCTX Canada
- IRIX United States
- Employees
- BCTX N/A
- IRIX N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- IRIX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- BCTX Health Care
- IRIX Health Care
- Exchange
- BCTX Nasdaq
- IRIX Nasdaq
- Market Cap
- BCTX 21.8M
- IRIX 20.2M
- IPO Year
- BCTX N/A
- IRIX 1996
- Fundamental
- Price
- BCTX $11.00
- IRIX $1.05
- Analyst Decision
- BCTX Strong Buy
- IRIX
- Analyst Count
- BCTX 1
- IRIX 0
- Target Price
- BCTX $40.00
- IRIX N/A
- AVG Volume (30 Days)
- BCTX 89.1K
- IRIX 55.4K
- Earning Date
- BCTX 10-16-2025
- IRIX 11-11-2025
- Dividend Yield
- BCTX N/A
- IRIX N/A
- EPS Growth
- BCTX N/A
- IRIX N/A
- EPS
- BCTX N/A
- IRIX N/A
- Revenue
- BCTX N/A
- IRIX $49,744,000.00
- Revenue This Year
- BCTX N/A
- IRIX $9.61
- Revenue Next Year
- BCTX $380.95
- IRIX N/A
- P/E Ratio
- BCTX N/A
- IRIX N/A
- Revenue Growth
- BCTX N/A
- IRIX 0.09
- 52 Week Low
- BCTX $6.00
- IRIX $0.78
- 52 Week High
- BCTX $190.50
- IRIX $1.95
- Technical
- Relative Strength Index (RSI)
- BCTX 45.44
- IRIX 43.17
- Support Level
- BCTX $11.75
- IRIX $1.00
- Resistance Level
- BCTX $13.43
- IRIX $1.09
- Average True Range (ATR)
- BCTX 1.07
- IRIX 0.04
- MACD
- BCTX -0.34
- IRIX 0.01
- Stochastic Oscillator
- BCTX 6.12
- IRIX 36.31
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About IRIX IRIDEX Corporation
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.